Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Abstract : The adherence profile of HIV-infected patients predicts the therapeutic outcome, in particular during the early phase of antiretroviral therapy (ART). We conducted a prospective observational multicenter trial monitoring adherence and virological and immunological parameters over the initial 6 months of treatment. Thirty-five subjects were starting a treatment regimen including atazanavir, ritonavir, and emtricitabine-tenofovir. Adherence was assessed using self-completed questionnaires, announced pill counts, and the medication event monitoring system (MEMS) for each drug. Three MEMS measures were defined: the percentages of doses taken, days with the correct dosing, and doses taken on time (± 3 h). Dynamic virological suppression (DVS) was defined as a reduction in the plasma HIV-RNA level of >1 log10 per month or <40 copies/ml. The cumulative treatment time was 5,526 days. A high level of adherence was observed. The MEMS-defined adherence for correct dosing (-0.68% per 4-week period, P < 0.03) and timing compliance (-1.60% per 4-week period, P < 0.003) decreased significantly over time. The MEMS-defined adherence data were concordant with the pill counts during the trial but not with the data from the questionnaires. The median [range] percentages of doses taken (100% [50 to 102]), days with the correct dosing (95% [41 to 100]), and doses taken on time (86% [32 to 100]) were significantly associated with DVS in separate models. Among these three measures, the percentage of doses taken on time had the greatest ability to predict DVS. Timing compliance should be supported to optimize DVS during the early phase of treatment by once-daily boosted protease inhibitor-based ART. (This study has been registered at ClinicalTrials.gov under registration no. NCT00528060.).
Type de document :
Article dans une revue
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (5), pp.2265-71. 〈10.1128/AAC.02605-12〉
Liste complète des métadonnées

Littérature citée [37 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00801312
Contributeur : Thu Thuy Nguyen <>
Soumis le : mercredi 4 septembre 2013 - 07:00:05
Dernière modification le : mardi 27 mars 2018 - 15:22:02
Document(s) archivé(s) le : dimanche 2 avril 2017 - 13:35:05

Fichier

Revised_paper_final_V2.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

USPC | CESP | UVSQ

Citation

Jean-Jacques Parienti, Aurélie Barrail-Tran, Xavier Duval, Georges Nembot, Diane Descamps, et al.. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2013, 57 (5), pp.2265-71. 〈10.1128/AAC.02605-12〉. 〈inserm-00801312〉

Partager

Métriques

Consultations de la notice

2221

Téléchargements de fichiers

262